A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease
Phase 1
- Conditions
- Celiac diseaseMedDRA version: 20.0Level: LLTClassification code: 10007864Term: Celiac disease Class: 10017947Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2022-502817-27-00
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method